Use of psychotropic medication during pregnancy and the postpartum period

Women's Health

Volumn 9, Issue 6, 2013, Pages 605-615

  Pearlstein, Teri ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

antidepressant; antiepileptic; antipsychotic; birth outcome; congenital malformations; depression; lithium; persistent pulmonary hypertension of the newborn; postnatal adaptation syndrome; pregnancy

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CITALOPRAM; DOXEPIN; ETIRACETAM; FLUOXETINE; GABAPENTIN; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; VALPROIC ACID; VENLAFAXINE;

ADAPTATION SYNDROME; ANXIETY; APGAR SCORE; AUTISM; BIPOLAR DISORDER; BREAST FEEDING; CARDIOVASCULAR MALFORMATION; CHILD DEVELOPMENT; CONGENITAL MALFORMATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG USE; EBSTEIN ANOMALY; EXERCISE; HUMAN; INTELLIGENCE QUOTIENT; LONG TERM EXPOSURE; LOW BIRTH WEIGHT; PATIENT MONITORING; PREGNANCY; PREMATURE LABOR; PRENATAL STRESS; PSYCHOTHERAPY; PUERPERAL DEPRESSION; PULMONARY HYPERTENSION; REVIEW; SCHIZOPHRENIA; SMALL FOR DATE INFANT; SPINAL DYSRAPHISM; SPONTANEOUS ABORTION; TERATOGENICITY; TRANSCRANIAL MAGNETIC STIMULATION;

ABORTION, SPONTANEOUS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BREAST FEEDING; CONGENITAL ABNORMALITIES; DEPRESSION, POSTPARTUM; DEPRESSIVE DISORDER; FEMALE; HUMANS; INFANT, NEWBORN; MENTAL DISORDERS; PERSISTENT FETAL CIRCULATION SYNDROME; PREGNANCY; PREGNANCY COMPLICATIONS; PREMATURE BIRTH; PRENATAL EXPOSURE DELAYED EFFECTS; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS; PUERPERAL DISORDERS;

EID: 84887249702     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.13.54     Document Type: Review

References (93)

1. Gavin NI, Gaynes BN, Lohr KN, Meltzer-Brody S, Gartlehner G, Swinson T. Perinatal depression: a systematic review of prevalence and incidence. Obstet. Gynecol. 106(5 Pt 1), 1071-1083 (2005). (Pubitemid 41532916)
2. Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ. A meta-ana lysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch. Gen. Psychiatry 67(10), 1012-1024 (2010).
3. Mauri M, Oppo A, Borri C, Banti S. Suicidality in the perinatal period: comparison of two self-report instruments. Results from PND-ReScU. Arch. Womens Ment. Health 15(1), 39-47 (2012).
4. Wisner KL, Sit DK, McShea MC et al. Onset timing, thoughts of self-harm, and diagnoses in postpartum women with screen-positive depression fndings. JAMA Psychiatry 70 (5), 490-498 (2013).
5. Pearlstein T, Howard M, Salisbury A, Zlotnick C. Postpartum depression. Am. J. Obstet. Gynecol. 200(4), 357-364 (2009).
6. Hanley GE, Oberlander TF. Neurodevelopmental outcomes following prenatal exposure to serotonin reuptake inhibitor antidepressants: a 'social teratogen' or moderator of developmental risk? Birth Defects Res. A Clin. Mol. Teratol. 94(8), 651-659 (2012).
7. Grigoriadis S, VonderPorten EH, Mamisashvili L et al. The impact of maternal depression during pregnancy on perinatal outcomes: a systematic reveiw and meta-analysis. J. Clin. Psychiatry 74(4), e321-e341 (2013).
8. Van Dijk AE, Van Eijsden M, Stronks K, Gemke RJ, Vrijkotte TG. Maternal depressive symptoms, serum folate status, and pregnancy outcome: results of the Amsterdam born children and their development study. Am. J. Obstet. Gynecol. 203(6), 563.e561-e567 (2010).
9. Mitchell AA, Gilboa SM, Werler MM et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am. J. Obstet. Gynecol. 205(1), 51.e51-e58 (2011).
10. Bakker MK, Kolling P, van den Berg PB, de Walle HE, de Jong van den Berg LT. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from The Netherlands. Br. J. Clin. Pharmacol. 65(4), 600-606 (2008). (Pubitemid 351365128)
11. Petersen I, Gilbert RE, Evans SJ, Man SL, Nazareth I. Pregnancy as a major determinant for discontinuation of antidepressants: an ana lysis of data from The Health Improvement Network. J. Clin. Psychiatry 72(7), 979-985 (2011).
12. Cohen LS, Altshuler LL, Harlow BL et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 295(5), 499-507 (2006). (Pubitemid 43200344)
13. Yonkers KA, Gotman N, Smith MV et al. Does antidepressant use attenuate the risk of a major depressive episode in pregnancy? Epidemiology 22(6), 848-854 (2011).
14. Sit D, Perel JM, Wisniewski SR, Helsel JC, Luther JF, Wisner KL. Mother-infant antidepressant concentrations, maternal depression, and perinatal events. J. Clin. Psychiatry 72(7), 994-1001 (2011).
15. Yonkers KA, Wisner KL, Stewart DE et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet. Gynecol. 114(3), 703-713 (2009).
16. Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol. Med. 40(10), 1723-1733 (2010).
17. Nakhai-Pour HR, Broy P, Berard A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ 182(10), 1031-1037 (2010).
18. Ross LE, Grigoriadis S, Mamisashvili L et al. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-ana lysis. JAMA Psychiatry 70(4), 436-443 (2013).
19. Yonkers KA, Norwitz ER, Smith MV et al. Depression and serotonin reuptake inhibitor treatment as risk factors for preterm birth. Epidemiology 23(5), 677-685 (2012).
20. Palmsten K, Hernandez-Diaz S. Can nonrandomized studies on the safety of antidepressants during pregnancy convincingly beat confounding, chance, and prior beliefs? Epidemiology 23(5), 686-688 (2012).
21. Byatt N, Deligiannidis KM, Freeman MP. Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatr. Scand. 127(2), 94-114 (2013).
22. Grigoriadis S, VonderPorten EH, Mamisashvili L et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-ana lysis of the best evidence. J. Clin. Psychiatry 74(4), e293-e308 (2013).
23. Myles N, Newall H, Ward H, Large M. Systematic meta-ana lysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. Aust. NZ J. Psychiatry doi: 10.1177/0004867413492219 (2013) (Epub ahead of print).
24. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet. Gynecol. 111(4), 1001-1020 (2008).
25. Jimenez-Solem E, Andersen JT, Petersen M et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open 2(3), pii: e001148 (2012).
26. Einarson A. The importance of critical evaluation of the literature regarding safety of antidepressant use in pregnancy. Acta Psychiatr. Scand. 127(2), 115-116 (2013).
27. Kennedy D. Choosing an SSRI in pregnancy: clinical context versus statistical signifcance. Aust. N. Z. J. Psychiatry doi:10.1177/0004867413500697 (2013) (Epub ahead of print).
28. 't Jong GW, Einarson T, Koren G, Einarson A. Antidepressant use in pregnancy and persistent pulmonary hypertension of the newborn (PPHN): a systematic review. Reprod. Toxicol. 34(3) 293-297 (2012).
29. Occhiogrosso M, Omran SS, Altemus M. Persistent pulmonary hypertension of the newborn and selective serotonin reuptake inhibitors: lessons from clinical and translational studies. Am. J. Psychiatry 169(2), 134-140 (2012).
30. Kieler H, Artama M, Engeland A et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the fve Nordic countries. BMJ 344, d8012 (2012).
31. Galbally M, Gentile S, Lewis AJ. Further fndings linking SSRIs during pregnancy and persistent pulmonary hypertension of the newborn: clinical implications. CNS Drugs 26(10), 813-822 (2012).
32. Grigoriadis S, VonderPorten EH, Mamisashvili L et al. The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-ana lysis. J. Clin. Psychiatry 74(4), e309-e320 (2013).
33. Moses-Kolko EL, Bogen D, Perel J et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 293(19), 2372-2383 (2005). (Pubitemid 40676760)
34. Salisbury AL, Wisner KL, Pearlstein T, Battle CL, Stroud L, Lester BM. Newborn neurobehavioral patterns are differentially related to prenatal maternal major depressive disorder and serotonin reuptake inhibitor treatment. Depress. Anxiety 28(11), 1008-1019 (2011).
35. Wisner KL, Bogen DL, Sit D et al. Does fetal exposure to SSRIs or maternal depression impact infant growth? Am. J. Psychiatry 170(5), 485-493 (2013).
36. de Vries NK, van der Veere CN, Reijneveld SA, Bos AF. Early neurological outcome of young infants exposed to selective serotonin reuptake inhibitors during pregnancy: results from the observational SMOK study. PLoS ONE 8(5), e64654 (2013).
37. Hanley GE, Brain U, Oberlander TF. Infant developmental outcomes following prenatal exposure to antidepressants, and maternal depressed mood and positive affect. Early Hum. Dev. 89(8), 519-524 (2013).
38. Nulman I, Koren G, Rovet J et al. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am. J. Psychiatry 169(11), 1165-1174 (2012).
39. Pedersen LH, Henriksen TB, Bech BH, Licht RW, Kjaer D, Olsen J. Prenatal antidepressant exposure and behavioral problems in early childhood-a cohort study. Acta Psychiatr. Scand. 127(2), 126-135 (2013).
40. Gentile S. Neurodevelopmental effects of prenatal exposure to psychotropic medications. Depress. Anxiety 27(7), 675-686 (2010).
41. Rai D, Lee BK, Dalman C, Golding J, Lewis G, Magnusson C. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ 346, f2059 (2013).
42. Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch. Gen. Psychiatry 68(11), 1104-1112 (2011).
43. de Vera MA, Berard A. Antidepressant use during pregnancy and the risk of pregnancy-induced hypertension. Br. J. Clin. Pharmacol. 74(2), 362-369 (2012).
44. Toh S, Mitchell AA, Louik C, Chambers CD, Hernandez-Diaz S. Selective serotonin reuptake inhibitor use and risk of gestational hypertension. Am. J. Psychiatry 166(3), 320-328 (2009).
45. Palmsten K, Huybrechts KF, Michels KB et al. Antidepressant use and risk for preeclampsia. Epidemiology 24(5), 682-691 (2013).
46. Dubnov-Raz G, Juurlink DN, Fogelman R et al. Antenatal use of selective serotonin-reuptake inhibitors and QT interval prolongation in newborns. Pediatrics 122(3), e710-e715 (2008).
47. Ban L, Tata LJ, West J, Fiaschi L, Gibson JE. Live and non-live pregnancy outcomes among women with depression and anxiety: a population-based study. PLoS ONE 7(8), e43462 (2012).
48. Colvin L, Slack-Smith L, Stanley FJ, Bower C. Early morbidity and mortality following in utero exposure to selective serotonin reuptake inhibitors: a population-based study in western Australia. CNS Drugs 26(7), e1-e14 (2012).
49. Jimenez-Solem E, Andersen JT, Petersen M et al. SSRI use during pregnancy and risk of stillbirth and neonatal mortality. Am. J. Psychiatry 170(3), 299-304 (2013).
50. Stephansson O, Kieler H, Haglund B et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 309(1), 48-54 (2013).
51. Hunter SK, Mendoza JH, D'anna K et al. Antidepressants may mitigate the effects of prenatal maternal anxiety on infant auditory sensory gating. Am. J. Psychiatry 169(6), 616-624 (2012).
52. Weikum WM, Oberlander TF, Hensch TK, Werker JF. Prenatal exposure to antidepressants and depressed maternal mood alter trajectory of infant speech perception. Proc. Natl Acad. Sci. USA 109(Suppl. 2), 17221-17227 (2012).
53. Weikum WM, Mayes LC, Grunau RE, Brain U, Oberlander TF. The impact of prenatal serotonin reuptake inhibitor (SRI) antidepressant exposure and maternal mood on mother-infant interactions at 3 months of age. Infant Behav. Dev. 36(4), 485-493 (2013).
54. Berle JO, Spigset O. Antidepressant use during breastfeeding. Curr. Womens Health Rev. 7(1), 28-34 (2011).
55. Rowe H, Baker T, Hale TW. Maternal medication, drug use, and breastfeeding. Pediatr. Clin. North Am. 60(1), 275-294 (2013).
56. Richards EM, Payne JL. The management of mood disorders in pregnancy: alternatives to antidepressants. CNS Spectr. 18(5), 261-271 (2013).
57. Tjoa C, Pare E, Kim DR. Unipolar depression during pregnancy: nonpharmacologic treatment options. Womens Health 6(4), 565-576 (2010).
58. Robakis TK, Williams KE. Biologically based treatment approaches to the patient with resistant perinatal depression. Arch. Womens Ment. Health 16(5), 343-351 (2013).
59. Bellantuono C, Tofani S, Di Sciascio G, Santone G. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. Gen. Hosp. Psychiatry 35(1), 3-8 (2013).
60. Wikner BN, Stiller CO, Bergman U, Asker C, Kallen B. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol. Drug Saf. 16(11), 1203-1210 (2007). (Pubitemid 350120645)
61. Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res. B Dev. Reprod. To x i c o l. 83(1), 68-76 (2008). (Pubitemid 351317794)
62. Reis M, Kallen B. Combined use of selective serotonin reuptake inhibitors and sedatives/hypnotics during pregnancy: risk of relatively severe congenital malformations or cardiac defects. A register study. BMJ Open 3(2), e002166 (2013).
63. Kallen B, Reis M. Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy. J. Clin. Psychopharmacol. 32(5), 608-614 (2012).
64. Kelly LE, Poon S, Madadi P, Koren G. Neonatal benzodiazepines exposure during breastfeeding. J. Pediatr. 161(3), 448-451 (2012).
65. McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profle: a systematic review and meta-analysis. Lancet 379(9817), 721-728 (2012).
66. Galbally M, Snellen M, Walker S, Permezel M. Management of antipsychotic and mood stabilizer medication in pregnancy: recommendations for antenatal care. Aust. NZ J. Psychiatry 44(2), 99-108 (2010).
67. Yonkers KA, Wisner KL, Stowe Z et al. Management of bipolar disorder during pregnancy and the postpartum period. Am. J. Psychiatry 161(4), 608-620 (2004). (Pubitemid 38445503)
68. Bogen DL, Sit D, Genovese A, Wisner KL. Three cases of lithium exposure and exclusive breastfeeding. Arch. Womens Ment. Health 15(1), 69-72 (2012).
69. van der Lugt NM, van de Maat JS, van Kamp IL, Knoppert-van der Klein EA, Hovens JG, Walther FJ. Fetal, neonatal and developmental outcomes of lithium-exposed pregnancies. Early Hum. Dev. 88(6), 375-378 (2012).
70. Vajda FJ, O'Brien TJ, Graham J, Lander CM, Eadie MJ. Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurol. Scand. 128(4), 228-234 (2013).
71. Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. Lancet Neurol. 11(9), 803-813 (2012).
72. Bath KG, Scharfman HE. Impact of early life exposure to antiepileptic drugs on neurobehavioral outcomes based on laboratory animal and clinical research. Epilepsy Behav. 26(3), 427-439 (2013).
73. Meador KJ, Baker GA, Browning N et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 12(3), 244-252 (2013).
74. Christensen J, Gronborg TK, Sorensen MJ et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 309(16), 1696-1703 (2013).
75. Bromley RL, Mawer GE, Briggs M et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. J. Neurol. Neurosurg. Psychiatry 84(6), 637-643 (2013).
76. Jentink J, Dolk H, Loane MA et al. Intrauterine exposure to carbamazepine and specifc congenital malformations: systematic review and case-control study. BMJ 341, c6581 (2010).
77. Cummings C, Stewart M, Stevenson M, Morrow J, Nelson J. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch. Dis. Child. 96(7), 643-647 (2011).
78. Veiby G, Daltveit AK, Schjolberg S et al. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia 54(8), 1462-1472 (2013).
79. Man SL, Petersen I, Thompson M, Nazareth I. Antiepileptic drugs during pregnancy in primary care: a UK population based study. PLoS ONE 7(12), e52339 (2012).
80. Holmes LB, Hernandez-Diaz S. Newer anticonvulsants: lamotrigine, topiramate and gabapentin. Birth Defects Res. A Clin. Mol. Teratol. 94(8), 599-606 (2012).
81. Reimers A, Brodtkorb E. Second-generation antiepileptic drugs and pregnancy: a guide for clinicians. Expert Rev. Neurother. 12(6), 707-717 (2012).
82. Margulis AV, Mitchell AA, Gilboa SM et al. Use of topiramate in pregnancy and risk of oral clefts. Am. J. Obstet. Gynecol. 207(5), 405.e401-e407 (2012).
83. Fujii H, Goel A, Bernard N et al. Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study. Neurology 80 (17), 1565-1570 (2013).
84. Molgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 305(19), 1996-2002 (2011).
85. Mawhinney E, Craig J, Morrow J et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology 80(4), 400-405 (2013).
86. Shallcross R, Bromley RL, Irwin B, Bonnett LJ, Morrow J, Baker GA. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology 76(4), 383-389 (2011).
87. Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr. Bull. 36(3), 518-544 (2010).
88. Habermann F, Fritzsche J, Fuhlbruck F et al. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J. Clin. Psychopharmacol. 33(4), 453-462 (2013).
89. Johnson KC, Laprairie JL, Brennan PA, Stowe ZN, Newport DJ. Prenatal antipsychotic exposure and neuromotor performance during i n fa nc y. Arch. Gen. Psychiatry 69(8), 787-794 (2012).
90. Toh S, Li Q, Cheetham TC et al. Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a population-based study of 585, 615 deliveries. Arch. Womens Ment. Health 16(2), 149-157 (2013).
91. Boden R, Lundgren M, Brandt L, Reutfors J, Kieler H. Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch. Gen. Psychiatry 69(7), 715-721 (2012).
92. Peng M, Gao K, Ding Y et al. Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants: a case-controlled, prospective study. Psychopharmacology (Berl.) 228(4), 577-584 (2013).
93. Gentile S. Infant safety with antipsychotic therapy in breast-feeding: a systematic review. J. Clin. Psychiatry 69(4), 666-673 (2008). (Pubitemid 351792344)